Notas de prensa
- Sin apartado
- General
Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease
Apr 11, 2005 (BUSINESS WIRE) -- Most people with chronic kidney disease die from cardiovascular problems before ever receiving dialysis or a transplant. Now there´s a new clinical trial called TREAT -- Trial To Reduce Cardiovascular Events with Aranesp Therapy. The goal of the trial is to determine if treating anemia will reduce cardiovascular events in people with chronic kidney disease and Type 2 diabetes.
Radio News Feature
You can reach the story directly by going to http://www.newstream.com/home.aspx?story=30339
This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos.
If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.
SOURCE: Newstream and Amgen
Newstream, New York info@newstream.com
![El 45% de los pacientes con hipofosfatemia ligada al cromosoma X (XLH) padece hipertensión arterial, un porcentaje significativamente mayor al de la población general[1]](https://farmanews.com/images/user_no_photo2.jpg)
